These organoids serve as valuable preclinical models for assessing the anti-tumor efficacy of SKP2 inhibitors (Zhang et al., 2024a), and for validating the expression patterns of PDGFD and PDGFRB, as well as the spatial distribution and binding characteristics of ligand-receptor interactions (Huang Y. et al., 2024). The gene discussed is SKP2; the disease is neoplasm.